

January 2007 DURB Meeting Summary

Issue	Attachment*	Action	Notes
Roll Call			Present: Dr. Swee, Dr. Gooen, Dr. Woodward, Dr. Marcus, Ms, Rodriquez, Mr. Schafer, Dr. Moynihan, Ms. Olson, Dr. Barberio, Dr. Moore, Dr. Condoluci, Dr. Lichtbroun Absent: Dr. Cavalieri
Review of minutes	Pages 3-6; Tab 1	Approved	Minutes from the October 2006 meeting were approved.
Secretary's Report	Page 7; Tab 2		All previous recommendations have been accepted and implemented. A recommendation regarding the reporting of denials was sent to the Managed Care Office, and a quarterly report will be prepared by the State for the Board. The serotonin syndrome publication is being worked on, and is slowed down by difficulty with claims data.
Business			
A. Newsletters			The comment period for the newsletters will close February 1, and the State will proceed with distribution.
B. Adverse Drug Reaction (ADR) data		Tabled	Due to difficulties in data collection, discussion on this topic was tabled.
C. Suboxone/opioid use	Pages 9-18; Tab 3	Recommendation	The data was presented for Oct -Dec 2006. Since many claims involved different prescribers, it was agreed that the state should use the drug-drug interaction edit to flag claims for opioids when suboxone is being used. A protocol will be presented at the April meeting.
D. GCSFs	Pages 19-59; Tab 4	Recommendation	The Board recommended that the State adopt the protocol as presented.
E. Methadone	Pages 61-66; Tab 5	Recommendation with revision	The Board recommended that the State adopt the protocol for methadone as presented, but that the title be revised to reflect that it refers to methadone used for pain management.
F. Second Generation Antihistamines	Pages 67-68; Tab 6	Recommendation	The Board recommended that the State undertake a pilot program offering coverage of OTC loratadine, as a cost-effective alternative for appropriate patients. The response to the Unisys survey was very positive; 77% of the respondents indicated that they would prescribe

January 2007 DURB Meeting Summary

Issue	Attachment*	Action	Notes
			an OTC product if coverage was provided.
H. Informational Highlights			
1. Edit update	Page 69;Tab 7		Table updates were noted.
2. Top 200 drugs	Pages		Review of the top 200 drugs presented led to a discussion of who the different Medicaid populations are. As part of the next meeting, there will be a short presentation describing the breakdown. Dr. Swee asked the Board to review the list of drugs for the next meeting, and suggest other areas where an OTC initiative may be appropriate
3. Unisys reports	Pages		No comments were noted
H. Action Items			
1. Adverse Drug Reactions 2. Newsletters 3. Suboxone® 4. OTC loratadine 5. Methadone 6. GCSFs 7. Serotonin syndrome 8. HMO reporting			1. State to continue to try to obtain data from claims regarding ADRs 2. Accept comments until Feb 1, and then proceed with distribution. 3. Recommendation to Commissioners; prepare protocol for use of opioids 4. Recommendation to Commissioners 5. Recommendation to Commissioners 6. Recommendation to Commissioners 7. State to prepare newsletter and data for Board review 8. State to prepare quarterly report on denials